Figures & data
Figure 1 Tear film disruption caused by instillation of a single drop of BAK (0.01%).
Abbreviation: BAK, benzalkonium chloride.
![Figure 1 Tear film disruption caused by instillation of a single drop of BAK (0.01%).](/cms/asset/67080e4d-7a57-47dd-89c5-423ca8b4d816/doph_a_150816_f0001_c.jpg)
Figure 2 Ocular symptoms and signs with preservative-added and preservative-free glaucoma medications.
![Figure 2 Ocular symptoms and signs with preservative-added and preservative-free glaucoma medications.](/cms/asset/32778f89-eb8e-4ba2-9c19-f12b8f179c7d/doph_a_150816_f0002_b.jpg)
Figure 3 Hyperemia in patients receiving preservative-added or preservative-free glaucoma medication.
![Figure 3 Hyperemia in patients receiving preservative-added or preservative-free glaucoma medication.](/cms/asset/88c64c7a-4660-419b-a515-117947d393fe/doph_a_150816_f0003_b.jpg)
Figure 4 Ocular signs and symptoms in patients receiving preservative-added or preservative-free glaucoma medication.
![Figure 4 Ocular signs and symptoms in patients receiving preservative-added or preservative-free glaucoma medication.](/cms/asset/c6cfef23-54f1-4b74-8d31-5317c510e58f/doph_a_150816_f0004_b.jpg)
Figure 5 Reduction in ocular symptoms following switch from preservative-added eye drops to preservative-free eye drops.
![Figure 5 Reduction in ocular symptoms following switch from preservative-added eye drops to preservative-free eye drops.](/cms/asset/429e6b31-87df-4eb0-b448-0b6c9440bb1a/doph_a_150816_f0005_b.jpg)
Figure 6 Reduction in clinical signs following switch from preservative-added to preservative-free eye drops.
![Figure 6 Reduction in clinical signs following switch from preservative-added to preservative-free eye drops.](/cms/asset/ce2910e2-25b7-452e-9633-02d21ed84c82/doph_a_150816_f0006_b.jpg)
Figure 7 Proportion of patients experiencing symptoms between eye drop instillations.
![Figure 7 Proportion of patients experiencing symptoms between eye drop instillations.](/cms/asset/d99ed5eb-0fec-4cae-a94a-8b253341c531/doph_a_150816_f0007_b.jpg)
Figure 8 Emergence of ocular symptoms on commencement of glaucoma treatment.
Abbreviation: MGD, meibomian gland dysfunction.
![Figure 8 Emergence of ocular symptoms on commencement of glaucoma treatment.](/cms/asset/51dc2c01-53c8-4797-91f8-011c5b2f1aa4/doph_a_150816_f0008_b.jpg)